Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
EFFECTIVENESS AND TOXICITY OF PREOPERATIVE THERAPY IN STAGE IIIA NONSMALL CELL LUNG-CANCER INCLUDING THE MEMORIAL SLOAN-KETTERING EXPERIENCE WITH INDUCTION MVP IN PATIENTS WITH BULKY MEDIASTINAL LYMPH-NODE METASTASES (CLINICAL N2)
Autore:
KRIS MG; PISTERS KMW; GINSBERG RJ; RIGAS JR; MILLER VA; GRANT SC; GRALLA RJ; HEELAN RT; MARTINI N;
Indirizzi:
MEM SLOAN KETTERING CANC CTR,1275 YORK AVE NEW YORK NY 10021 CORNELL UNIV,COLL MED NEW YORK NY 00000 DEPT MED,DIV SOLID TUMOR ONCOL,THORAC ONCOL SERV NEW YORK NY 00000 DEPT SURG,THORAC SURG SERV NEW YORK NY 00000 DEPT RADIOL NEW YORK NY 00000
Titolo Testata:
Lung cancer
, volume: 12, anno: 1995, supplemento:, 1
pagine: 47 - 57
SICI:
0169-5002(1995)12:<47:EATOPT>2.0.ZU;2-A
Fonte:
ISI
Lingua:
ENG
Soggetto:
LEUKEMIA GROUP-B; PHASE-II; RANDOMIZED TRIAL; COMBINATION CHEMOTHERAPY; NEOADJUVANT CHEMOTHERAPY; VINDESINE; CARCINOMA; MITOMYCIN; CISPLATIN; RESECTION;
Keywords:
NONSMALL CELL LUNG CANCER; MULTIMODALITY THERAPY; INDUCTION CHEMOTHERAPY; NEOADJUVANT CHEMOTHERAPY; CISPLATIN; MEDIASTINAL LYMPH NODE METASTASES;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
38
Recensione:
Indirizzi per estratti:
Citazione:
M.G. Kris et al., "EFFECTIVENESS AND TOXICITY OF PREOPERATIVE THERAPY IN STAGE IIIA NONSMALL CELL LUNG-CANCER INCLUDING THE MEMORIAL SLOAN-KETTERING EXPERIENCE WITH INDUCTION MVP IN PATIENTS WITH BULKY MEDIASTINAL LYMPH-NODE METASTASES (CLINICAL N2)", Lung cancer, 12, 1995, pp. 47-57

Abstract

The use of preoperative chemotherapy with mitomycin, vinblastine and cisplatin (MVP) has led to improved complete resection rates and survival in Stage IIIA non-small cell lung cancer with bulky, ipsilateral, mediastinal lymph node metastases (Clinical N2 disease). The addition of preoperative irradiation has also been explored with results not substantially different from preoperative cisplatin-based chemotherapy alone: While preoperative chemotherapy has been shown to be feasible, the toxicity of both the chemotherapy and the subsequent resection is of concern with an overall treatment-related mortality of nearly 8%. The careful selection of patients, swift management of neutropenia, and meticulous perioperative pulmonary care has the potential to reduce the mortality from multimodality therapy. Having shown survival benefit in multiple single-institution and randomized trials, induction chemotherapy followed by surgery or irradiation is now the treatment of choice for patients with Stage IIIA non-small cell lung cancer with mediastinal lymph node metastases.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 01/12/20 alle ore 10:56:42